Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 80% Improvement Relative Risk Progression 56% Recovery 33% Time to viral- 27% Ivermectin for COVID-19  Rezk et al.  LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Prospective study of 320 patients in Egypt Lower progression (p=0.064) and faster viral clearance (p=0.01) c19ivm.org Rezk et al., Zagazig University Medica.., Oct 2021 Favors ivermectin Favors control

miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin

Rezk et al., Zagazig University Medical Journal, doi:10.21608/zumj.2021.92746.2329
Oct 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19ivm.org
Prospective 320 hospitalized moderate COVID-19+ patients in Egypt, 160 treated with ivermectin, showing lower mortality, improved recovery, and decreased cytokine expression with treatment. All patients were treated with HCQ. 7890/26-8-2020.
This is the 65th of 102 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 560 quintillion).
49 studies are RCTs, which show efficacy with p=0.00000038.
risk of death, 80.0% lower, RR 0.20, p = 0.50, treatment 0 of 160 (0.0%), control 2 of 160 (1.2%), NNT 80, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of progression, 55.6% lower, RR 0.44, p = 0.06, treatment 8 of 160 (5.0%), control 18 of 160 (11.2%), NNT 16, 2 weeks, including deaths.
risk of no recovery, 33.4% lower, RR 0.67, p = 0.27, treatment 14 of 145 (9.7%), control 20 of 138 (14.5%), NNT 21, 4 weeks, more patients were lost to followup in the control group.
time to viral-, 27.3% lower, relative time 0.73, p = 0.01, treatment 160, control 160.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rezk et al., 30 Oct 2021, prospective, Egypt, peer-reviewed, 4 authors, dosage 36mg days 1, 3, 6. Contact: nonnarezk@yahoo.com.
This PaperIvermectinAll
miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin
Noha A Rezk, Ashraf Elsayed Sileem, Doaa Mostafa Gad, Amr O Khalil
Zagazig University Medical Journal, doi:10.21608/zumj.2021.92746.2329
Background: The role of Ivermectin in improving the outcome of coronavirus disease of 2019 (COVID-19) symptoms was reported in several studies, while its effect on the pro-inflammatory cytokines triggering the cytokine storm is still not investigated. Method: This study aimed to investigate the role of Ivermectin on the proinflammatory cytokines in Covid-19 patients and correlated the results with the expression of miR-2909, miR-223-3p. Three hundred and twenty hospitalized patients with confirmed moderate-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were selected. The patients were divided into 2 groups: Group I treated with the Egyptian protocol of COVID-19 including (Ivermectin plus hydroxychloroquine). Group II was treated with the Egyptian protocol, including hydroxychloroquine and no Ivermectin. IL-6, IL-1b, procalcitonin, and gene expression of miR-2909, miR-223-3p, and Toll-like receptor 4 were done by real-time Polymerase Chain Reaction (PCR). Results : Patients treated with COVID-19 protocol including Ivermectin showed a significant decrease of cytokines levels (IL-6, IL-1, and procalcitonin), when compared with the other group, the cytokines levels improvement were positively correlated with miR-2029 expression and negatively correlated with the expression of miR-223-3p. Moderate ill COVID-19 patients treated with Ivermectin showed a significant decline in mortality rate and duration of hospital stay. Conclusion: Ivermectin is an effective drug in improving the outcome of SARS-CoV-2 patients with a significant decrease in mortality rate through decreasing cytokines expression via controlling miR-2029, miR-233-3p expressions.
References
Aggarwal, Baker, Evans, Haslam, G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome, Eur Respir J
Arora, Kaul, Sharma, Human coronary heart disease: importance of blood cellular miR-2909 RNomics, Mol Cell Biochem
Behera, Patro, Singh, Chandanshive, Pradhan, Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study, PLoS ONE
Behera, Patro, Singh, Chandanshive, R R, Pradhan, Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study, PLoS One
Bray, Rayner, Noël, Jans, Wagstaff, Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res
Caly, Druce, Catton, Da, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Chaccour, Brew, Garcia-Basteiro, Ivermectin and COVID-19: how a flawed database shaped the pandemic response of several Latin-American Countries − Blog − ISGlobal
Chen, Wang, Liu, Song, Lai et al., Inducible microRNA-223 down-regulation promotes TLR-triggered IL-6 and IL-1β production in macrophages by targeting STAT3, PLoS One
Chi, Ge, Wu, Zhang, Wu et al., Serum Cytokine and Chemokine profile in Relation to the Severity of Coronavirus disease 2019 (COVID-19) in China, J Infect Dis
Chowdhury, Shahbaz, Karim, Islam, Dan et al., A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients, EJMO
Diba, Alib, The broad-spectrum antiparasitic ivermectin against COVID-19, Kasr Al Ainy Med J
Dorhoi, Iannaccone, Farinacci, Fae´, Schreiber et al., MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment, J Clin Invest
Garibotto, Carta, Picciotto, Viazzi, Verzola, Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy, J Nephrol
Guzzo, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, Clin. Pharmacol
Götz, Magar, Dornfeld, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep
Lim, Lau, Garrett-Engele, Grimson, Schelter et al., Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs, Nature
Livak, Schmittgen, Analysis of Relative Gene Expression Data Using RealTime Quantitative PCR and the 22DDCt method, Egyptian Ministry of Health
Lundberg, Pinkham, Baer, Amaya, Narayanan et al., Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication, Antiviral Research
Lundstrom, Seyran, Pizzol, Adadi, El-Aziz, Viewpoint: Origin of SARS-CoV-2, Viruses
López-Medina, López, Hurtado, Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, JAMA
Mahmudpour, Roozbeh, Keshavarz, Farrokhi, Nabipour, COVID-19 cytokine storm: The anger of inflammation, Cytokine
Margariti, Zampetaki, Xiao, Zhou, Karamariti, Histone deacetylase 7 controls endothelial cell growth through modulation of betacatenin, Circ. Res
Mastrangelo, Pezzullo, Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother
Momekov, Momekova, Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens, Biotechnol Biotechnol Equipment
Noha, MicroRNA functions in animal development and human disease, Development
Palanisamy, Jakymiw, Van Tubergen, Silva, Kirkwood, Control of Cytokine mRNA Expression by RNA-binding Proteins and microRNAs, J Dent Res
Pascarella, Strumia, Piliego, Bruno, Buono et al., COVID-19 diagnosis, and management: a comprehensive review, J Intern Med
Peng, Wong, Tung, Chen, Chao et al., Computational modeling with forward and reverse engineering links signaling network and genomic regulatory responses: NF-kappaB signaling-induced gene expression responses in inflammation, BMC Bioinformatics
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of Ivermectin Is Associated with Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study, Chest
Rezk, Elsayed Sileem, Gad, Khalil, miRNA-223-3p, miRNA-2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin, Zagazig University Medical Journal
Seyran, Takayama, Uversky, Lundstrom, Palù et al., The structural basis of accelerated host cell entry by SARS-CoV-2 †, FEBS J
Sharma, Sharma, Arora, Kaul, Regulation of cellular Cyclin D1 gene by arsenic is mediated through miR-2909, Gene
Shouman, Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19
Sia, Mensah, Opoku-Agyemang, Mechanisms of ivermectin-induced wound healing, BMC Vet Res, doi:10.1186/s12917-020-02612-z
Slomiany, Slomiany, Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin, Inflammopharmacology
Sohn, Lee, Kim, Cheon, Jeong et al., COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis, J Korean Med Sci
Valle, Kim-Schulze, Hsin-Hui, Beckmann, Nirenberg et al., An inflammatory cytokine signature helps predict COVID-19 severity and death, Nat Med
Wang, Bai, Song, Fan, Hu et al., None, miR
Wang, Wu, Cheng, Jiang, Li, Overexpression of microRNA-223 inhibited the proinflammatory responses in Helicobacter pyloriinfection macrophages by down-regulating IRAK-1, Am J Transl Res
Wu, Niu, Zhao, Cheng, Lin, Impact of miR-223-3p and miR-2909 on inflammatory factors IL-6, IL-1ß, and TNF-α, and the TLR4/TLR2/NF-κB/STAT3 signaling pathway induced by lipopolysaccharide in human adipose stem cells, PLoS ONE
Yan, Ci, Chen, Chen, Li et al., Antiinflammatory effects of ivermectin in mouse model of allergic asthma, Res
Zhang, Song, Ci, An, Ju et al., Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Res
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit